Uterine

Researchers funded by the National Institutes of Health have developed a new imaging tool, called electromyometrial imaging (EMMI), to create real-time, three-dimensional images and maps of contractions during labor. The non-invasive…

Cara Murez TUESDAY, Feb. 21, 2023 (HealthDay News) -- Black women are not getting the tests they need to diagnose uterine cancer early, according to a new study.Previous research had found that Black…

For the first time, scientists at Northwestern Medicine have demonstrated a causal link between environmental phthalates (toxic chemicals found in everyday consumer products) and the increased growth of uterine fibroids, the most common…

Cara Murez TUESDAY, Oct. 25, 2022 (HealthDay News) -- A Missouri woman has sued L’Oréal and several other beauty product companies, alleging that their hair-straightening products caused her uterine…

Physician’s Briefing Staff THURSDAY, Oct. 20, 2022 (HealthDay News) -- Use of hair straightening products appears to be associated with incident uterine cancer, according to a study published online…

ANI Washington, October 19 Women who used chemical hair straightening products were at higher risk for uterine cancer compared to women who did not report using these products, according to…

Women who used chemical hair straightening products were at higher risk for uterine cancer compared to women who did not report using these products, according to a new study from the National Institutes of Health. The researchers found no…

New York, United States, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Uterine, ovarian, and cervical cervix cancers are the most common in women. Cervical cancer ranks fourth among women's cancers. Gynecological cancers result from epigenetic…

  -Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy- -Theramex to commercialize Yselty®; ObsEva to receive royalties on commercial sales,…

-Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy-   -Theramex to commercialize Yselty®; ObsEva to receive royalties on commercial sales,…